IRF5 recombinant protein: a bi-directional regulatory transcription factor with dual tumor-suppressive and oncogenic functions

Author: Senior Product Manager of UA Views：17

This article focuses on the molecular characteristics and immune functions of interferon regulatory factor 5 (IRF5), systematically elaborating its role as a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors in inflammation and autoimmune diseases, analyzing the tumor-suppressive mechanisms by which IRF5 inhibits growth and induces apoptosis through p21, Bax, and caspase 8, and promotes tumor regression through interferon production and immunomodulatory cascades, and exploring its other face of exerting oncogenic functions in specific cancers through hypomethylation-mediated overexpression and release of pro-inflammatory cytokines.

Recent Advances
Product Information

Recent Advances

IRF5 Recombinant Protein: A Bidirectional Regulatory Transcription Factor with Both Tumor-Suppressive and Oncogenic Functions

Brief introduction: This article focuses on the molecular characteristics and immune functions of interferon regulatory factor 5 (IRF5), systematically elaborating its role as a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors in inflammation and autoimmune diseases, analyzing its tumor-suppressive mechanisms of inhibiting growth and inducing apoptosis through p21, Bax, and caspase 8 as well as promoting tumor regression through interferon production and immunomodulatory cascades, and discussing the other side of its oncogenic function exerted through hypomethylation-mediated overexpression and proinflammatory cytokine release in specific cancers.

I. Molecular localization and immunological functional basis of IRF5.

In scope, the transcription factor interferon regulatory factor 5 is a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors such as Toll-like receptors. Consequently, IRF5 dysfunction is broadly associated with inflammation and autoimmune diseases. Over the past decades, dysregulated IRF5 expression has also been reported in hematological malignancies and solid cancers, supporting a role for IRF5 in malignant transformation, tumor immune regulation, clinical prognosis, and treatment response. As a stress-responsive protein, IRF5 can be activated downstream of pathogens, immune activation, DNA damage, and other triggers. In response to these triggers, IRF5 undergoes post-translational modifications and translocation from the cytoplasm to the nucleus; this "stress sensing—modification—nuclear translocation" activation mode determines the spatiotemporal specificity of IRF5 function and also constitutes the molecular basis for its differential effects in different cellular contexts.

II. Mechanisms of IRF5 as a tumor suppressor.

The tumor-suppressive function of IRF5 is achieved through two interrelated pathways. At the cell-autonomous level, after entering the nucleus, IRF5 inhibits growth and induces apoptosis through p21, Bax, Bak, and caspase 8 as a mechanism of growth control. This pathway acts directly on core molecules of cell cycle arrest and apoptotic execution, making IRF5 an internal control point that restricts abnormal cell proliferation under stress conditions. At the immunomodulatory level, or simultaneously, IRF5 induces immunomodulatory cascades involving interferon production, dendritic cell activation, cytotoxic T cell activation, and upregulation of the CXCL13-CXCR5 axis that drives tertiary lymphoid structures, ultimately leading to tumor regression. IRF5 further has cytoplasmic functions independent of its role as a transcriptional regulator and contributes to growth control and suppression of migratory and invasive potential. This dual mode of action, in which nuclear transcriptional regulation coexists with cytoplasmic non-transcriptional functions, gives the tumor-suppressive effects of IRF5 a multi-layered safeguard mechanism.

III. Molecular pathways of IRF5 inactivation in tumors.

IRF5 can be inactivated in tumor cells to evade these growth control mechanisms. Inactivation occurs at the genetic level through hypermethylation, viral infection, or oncogene drivers such as BCR-ABL and MYC. Viral infection can lead to IRF5 inactivation through upregulated viral protein expression and competitive binding. IRF5 can also be inactivated through post-translational modification via SUMOylation by TRIM28. With decreased IRF5 expression, cancer cell apoptosis and tumor immunity are suppressed. The diversity of these inactivation pathways indicates that IRF5 is an important selection pressure faced by tumor cells during malignant transformation; the fact that tumors weaken its function through multiple independent epigenetic and post-transcriptional mechanisms precisely reflects the biological importance of IRF5's tumor-suppressive function.

IV. Controversial evidence for IRF5 as an oncogene.

IRF5 has also been reported to have oncogenic functions. IRF5 can be hypomethylated, leading to overexpression or induction through virus-mediated promoter activation. IRF5 then activates AP-1 and downstream release of excessive proinflammatory cytokines, leading to immune evasion, angiogenesis, and uncontrolled tumor growth. In addition, IRF5 has been shown to activate oncogenes, and cytoplasmic IRF5 has been shown to induce proliferation and migration of some cancer cells. It has also been demonstrated to induce protein degradation of Wnt5a and E-cadherin, thereby increasing invasive capacity. These oncogenic functions form a sharp contrast with the aforementioned tumor-suppressive functions, suggesting that the net effect of IRF5 is highly dependent on cell type, subcellular localization, and the surrounding microenvironment. Therefore, understanding IRF5 function cannot be separated from its specific context, and any attempt to simply classify it as a tumor suppressor or oncogene may obscure its true biological complexity.

V. Therapeutic potential of IRF5 targeting the immune microenvironment.

At the level of therapeutic strategy, lipid nanoparticles loaded with IRF5 messenger RNA, with or without other molecules that increase IRF5 activation, and with or without surface tags that selectively target macrophages, constitute the core concept of IRF5 targeting the immune microenvironment. Lipid nanoparticles are systemically injected to target the immune microenvironment with the aim of polarizing macrophages toward M1. M1-like macrophages promote tumor cell death through recruitment of other immune cells, direct tissue damage, phagocytosis, and apoptosis. Although IRF5 deficiency drives an M2-like macrophage phenotype, induction or overexpression of IRF5 shifts macrophages away from M2-like polarization, thereby preventing macrophages from promoting invasion, angiogenesis, immune evasion, proliferation, and tissue remodeling. The core of this strategy lies in using IRF5 as a key switch for the direction of macrophage polarization, remodeling the pro-tumor M2-like microenvironment into an anti-tumor M1-like microenvironment.

VI. Conclusion.

In IRF5-related basic research and the development of tumor immunotherapy, high-quality recombinant IRF5 protein is a core tool for dissecting its DNA-binding properties, post-translational modification regulation, and protein-protein interactions. The His tag facilitates efficient purification through immobilized metal affinity chromatography and enables detection and capture via anti-His tag antibodies. To meet the needs of IRF5 function research and exploration of tumor immune regulatory mechanisms, Ulab provides IRF5 His Tag Protein, Human. This product is suitable for applications such as analysis of IRF5 binding activity to interferon gene promoters, studies on the effects of IRF5 post-translational modifications on nuclear translocation and transcriptional activity, exploration of IRF5-mediated macrophage polarization regulatory mechanisms, and development of immunotherapeutic strategies targeting IRF5.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next